CRO Services
Participate In a Study
About Us
Careers
Contact
FR
CRO Services
Participate In a Study
About Us
Careers
Contact
FR
Test
Post navigation
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
